Aaron Gerds, MD from Cleveland Clinics discusses patients showed symptomatic relief in Phase I Trial of Glasdegib and 35% of patients had at least a 20% improvement in their symptom burden at the 2017 American Society of Hematology.
Patients Showed Symptomatic Relief in Phase I Trial of Glasdegib – 35% of Patients had at least a 20% improvement in their Symptom Burden
